Ciclacillin

Ciclacillin
Systematic (IUPAC) name
(2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}- 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane- 2-carboxylic acid
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability Moderate
Protein binding <25%
Identifiers
CAS Number 3485-14-1 YesY
ATC code none
PubChem CID 19003
IUPHAR/BPS 4817
DrugBank DB01000 YesY
ChemSpider 17941 YesY
UNII 72ZJ154X86 YesY
KEGG D01334 YesY
ChEBI CHEBI:31444 YesY
ChEMBL CHEMBL1200356 N
Chemical data
Formula C15H23N3O4S
Molar mass 341.425 g/mol
 NYesY (what is this?)  (verify)

Ciclacillin (INN) or cyclacillin (USAN), trade names Cyclapen, Cyclapen-W, Vastcillin, and others, is an aminopenicillin antibiotic. Its spectrum of activity is similar to that of ampicillin, although it is less susceptible to beta-lactamases than ampicillin and has much higher bioavailability.[1] A large randomized, double-blind clinical trial published in 1978 also showed that ciclacillin is associated with significantly fewer and milder adverse effects than ampicillin;[2] later studies seemed to confirm this improved tolerability, at least in children.[3][4]

Ciclacillin has been superseded by newer antibiotics and is no longer in clinical use, at least in the United States.[5]

Synthesis

In an attempt to form orally active penicillins unrelated to ampicillin, use was made of the fact that certain spiro α-amino acids, such as Cycloleucine, are well absorbed orally and transported like normal amino acids.

Cyclacillin synthesis:[6]

Reaction of cyclohexanone with ammonium carbonate and KCN under the conditions of the Bucherer-Bergs reaction led to hydantoin 1. On acid hydrolysis, α-amino acid 2 resulted. Treatment with phosgene both protected the amino group and activated the carboxyl group toward amide formation (as 3) and reaction with 6-aminopenicillanic acid (6-APA) gave cyclacillin (4).

Interestingly, this artifice seems to have worked, since cyclacillin is more active in vivo than its in vitro spectrum suggests would be likely.

References

  1. Warren GH (1976). "Cyclacillin: microbiological and pharmacological properties and use in chemotherapy of infection - a critical appraisal". Chemotherapy 22 (3–4): 154–82. doi:10.1159/000221924. PMID 773605.
  2. Gold JA, Hegarty CP, Deitch MW, Walker BR (January 1979). "Double-blind clinical trials of oral cyclacillin and ampicillin". Antimicrob Agents Chemother 15 (1): 55–8. doi:10.1128/aac.15.1.55. PMC: 352600. PMID 371540.
  3. McLinn SE, Goldberg F, Kramer R, Saltstein E, Bomze JP, Deitch MW (October 1982). "Double-blind multicenter comparison of cyclacillin and amoxicillin for the treatment of acute otitis media". J Pediatr 101 (4): 617–21. doi:10.1016/S0022-3476(82)80724-5. PMID 6750067.
  4. McLinn SE, Kaplan J, West N (1983). "Multicenter comparison of cyclacillin and amoxicillin in the treatment of acute streptococcal pharyngitis". Clin Ther 5 (3): 299–304. PMID 6342785.
  5. Gorbach SL, Bartlett JG, Blacklow NR (2004). Infectious diseases (3rd ed.). Hagerstown, MD: Lippincott Williams & Wilkins. p. 186. ISBN 0-7817-3371-5. Retrieved on September 7, 2008 through Google Book Search.
  6. Alburn, H. E.; Clark, R. E.; Fletcher h, 3rd; Grant, N. H. (1967). "Synthesis of new broad-spectrum aminoalicyclic penicillins". Antimicrobial agents and chemotherapy 7: 586–9. PMID 5596194.

Further reading


This article is issued from Wikipedia - version of the Sunday, April 10, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.